https://www.nejm.org/doi/pdf/10.1056/NEJMoa2309719
0
0
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer | NEJM - nejm.org
10/21/23 at 2:30pm
Organization
nejm.org
Author
nejm.org
Details
15 words
Summarize
Create an account or login to join the discussion